CKD患者心血管风险亚组中药物治疗、经皮与外科冠脉血运重建的比较效果:Medicare受益者回顾性队列研究
该回顾性队列研究纳入34,385例CKD患者,按心血管风险分层比较PCI、CABG与优化药物治疗后的死亡和肾衰竭风险。低中风险患者中血运重建未降低死亡率,低风险者CABG与复合终点升高相关;高风险患者中CABG和PCI与较低死亡率相关,但CABG与肾衰竭风险升高相关。
要点
- 低中风险CKD患者中,PCI或CABG相比优化药物治疗未降低死亡率。
- 低风险CKD患者中,CABG与死亡或肾衰竭复合终点风险升高相关。
- 高风险CKD患者中,CABG和PCI与较低死亡率相关,但CABG与肾衰竭风险升高相关。
核心结论
- CKD患者心血管治疗结局因基线心血管风险而异,血运重建在低风险患者未改善生存,在高风险患者改善生存但CABG肾衰竭风险更高。
研究设计与样本
- 回顾性队列研究,纳入34,385例CKD患者,分为低风险(无既往心血管病)、中风险(有既往心血管病)和高风险(急性冠脉综合征)。
主要发现
- 低风险患者中,CABG与死亡或肾衰竭复合终点风险升高相关(HR 1.25,95%CI 1.02-1.53)。
- 中风险患者中,CABG与PCI均未与死亡率降低相关(HR分别为1.08和1.02)。
- 高风险患者中,CABG和PCI与较低死亡率相关(HR分别为0.57和0.70),但CABG与肾衰竭风险升高相关(HR 1.40,95%CI 1.16-1.69)。
临床怎么用
- 对于低至中风险CKD患者,优化药物治疗可能是合理的首选策略,血运重建未显示生存获益。
- 对于高风险CKD患者(如急性冠脉综合征),血运重建可改善生存,但需权衡CABG相关肾衰竭风险。
局限性
- 可能存在残余混杂;缺乏冠脉造影或左心室射血分数数据;治疗组间肾功能下降严重程度可能存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Prior studies suggesting that medical therapy is inferior to percutaneous (percutaneous coronary intervention [PCI]) or surgical (coronary artery bypass grafting [CABG]) coronary revascularization in chronic kidney disease (CKD) have not adequately considered medication optimization or baseline cardiovascular risk and have infrequently evaluated progression to kidney failure. We compared, separately, the risks for kidney failure and death after treatment with PCI, CABG, or optimized medical therapy for coronary disease among patients with CKD stratified by cardiovascular disease risk. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: 34,385 individuals with CKD identified from a national 20% Medicare sample who underwent angiography or diagnostic stress testing without (low risk) or with (medium risk) prior cardiovascular disease or who presented with acute coronary syndrome (high risk). EXPOSURES: PCI, CABG, or optimized medical therapy (defined by the addition of cardiovascular medications in the absence of coronary revascularization). OUTCOMES: Death, kidney failure, composite outcome of death or kidney failure. ANALYTICAL APPROACH: Adjusted relative rates of death, kidney failure, and the composite of death or kidney failure estimated from Cox proportional hazards models. RESULTS: Among low-risk patients, 960 underwent PCI, 391 underwent CABG, and 6,426 received medical therapy alone; among medium-risk patients, 1,812 underwent PCI, 512 underwent CABG, and 9,984 received medical therapy alone; and among high-risk patients, 4,608 underwent PCI, 1,330 underwent CABG, and 8,362 received medical therapy alone. Among low- and medium-risk patients, neither CABG (HRs of 1.22 [95% CI, 0.96-1.53] and 1.08 [95% CI, 0.91-1.29] for low- and medium-risk patients, respectively) nor PCI (HRs of 1.14 [95% CI, 0.98-1.33] and 1.02 [95% CI, 0.93-1.12], respectively) were associated with reduced mortality compared with medical therapy, but in low-risk patients, CABG was associated with a higher rate of the composite, death or kidney failure (HR, 1.25; 95% CI, 1.02-1.53). In high-risk patients, CABG and PCI were associated with lower mortality (HRs of 0.57 [95% CI, 0.51-0.63] and 0.70 [95% CI, 0.66-0.74], respectively). Also, in high-risk patients, CABG was associated with a higher rate of kidney failure (HR, 1.40; 95% CI, 1.16-1.69). LIMITATIONS: Possible residual confounding; lack of data for coronary angiography or left ventricular ejection fraction; possible differences in decreased kidney function severity between therapy groups. CONCLUSIONS: Outcomes associated with cardiovascular therapies among patients with CKD differed by baseline cardiovascular risk. Coronary revascularization was not associated with improved survival in low-risk patients, but was associated with improved survival in high-risk patients despite a greater observed rate of kidney failure. These findings may inform clinical decision making in the care of patients with both CKD and cardiovascular disease.
引用
- Charytan DM, Natwick T, Solid CA, et al. Comparative Effectiveness of Medical Therapy, Percutaneous Revascularization, and Surgical Coronary Revascularization in Cardiovascular Risk Subgroups of Patients With CKD: A Retrospective Cohort Study of Medicare Beneficiaries. Am J Kidney Dis. 2019. PMID: 31255335. doi:10.1053/j.ajkd.2019.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。